Blood Advances

Article	Citations
Receiving CAR T-cells gets faster, but not for all in need	167
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs	164
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.	139
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	127
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	120
BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice	120
MENIN MAINTENANCE THERAPY FOR ACUTE LEUKEMIA	112
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma	109
Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR Analysis	104
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML	103
Clinical Outcomes in Elderly Patients Treated Outside Clinical Studies: Highlighting the Octogenarian Experience	96
Interplay between iron metabolism, inflammation, and EPO-ERFE-Hepcidin axis in RDEB-associated chronic anemia	94
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia	90
Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study	90
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	87
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions	86
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel	85
Audit of B-cell Cancer Genes	84
Glucagon-Like Peptide 1 Receptor Agonists and Venous Thromboembolism in Type 2 Diabetes: A Target Trial Emulation	84
Factors associated with early quality of life response to palliative care during hematopoietic cell transplantation	84
A sweet deal: blocking NMDAR for safer t-PA in diabetes	83
Systemic Mastocytosis: Current Status and Challenges in 2024	83
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry	80
RNA-seq–based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia	79
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	77

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition	76
Differential sialic acid content in adult and neonatal fibrinogen mediates differences in clot polymerization dynamics	76
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response	76
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	74
Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia	73
Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma	72
Back from (BTKi) holiday	71
Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model	71
Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia	71
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI	70
Addressing and overcoming disparities in GVHD	70
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19	69
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort	67
Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant	67
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	66
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	64
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study	63
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question	63
G6b-B regulates an essential step in megakaryocyte maturation	62
Autologous transplant and second malignancies in MM	61
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma	60
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study	59
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy	59
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials	59
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA	58
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment	58
The fate of mitochondria during platelet activation	57
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	57
Tyrosine kinase inhibitor for CML: all the same?	57
Single-cell immune profiling reveals a developmentally distinct CD4+ GM-CSF+ T-cell lineage that induces GI tract GVHD	56
Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics	55
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	55
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens	55
ABO blood group type and risk of venous thromboembolism in patients with cancer	53
Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection	53
Patient-specific comorbidities as prognostic variables for survival in myelofibrosis	53
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia	53
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma	52
A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome	52
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia	52
JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes	51
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial	51
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia	51
Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo	51
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders	51
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia	51
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	51
Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis	50
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	50
Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy	50

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas	50
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	49
Peripheral megakaryocytes sound the alarm in COVID-19	49
A predictive model for bone marrow disease in cytopenia based on noninvasive procedures	49
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia	49
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	49
Anti-HK antibody reveals critical roles of a 20-residue HK region for Aβ-induced plasma contact system activation	49
A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD	49
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia	49
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	49
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience	48
Loss of early myeloid donor cell engraftment into the central nervous system with nonmyeloablative conditioning	48
Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2	48
Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels	48
13q12.2 deletions and FLT3 overexpression in acute leukemias	48
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment	47
Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant	47
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab	47
Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations	47
Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL	47
Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice	46
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study	46
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	45
Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease	45
ADP: the missing link between thrombosis and hemolysis	45
GPVI expression is linked to platelet size, age, and reactivity	45
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ	44
Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome	44
Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells	44
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia	44
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	44
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant	43
Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma	43
Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation	43
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia	43
CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia	43
Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia	42
Applying CRISPR-Cas9 screens to dissect hematological malignancies	42
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted	42
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study	42
Elevated RIPK3 correlates with disease burden in myelofibrosis	41
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study	41
Histone deacetylase-6 modulates the effects of 4°C platelets on vascular endothelial permeability	41
Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy	41
Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo	41
A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation	40
pH-dependent conformation of multimeric von Willebrand factor	40
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes	40
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas	40
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	40
Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis	39
Transfusion therapy for sickle cell disease: what’s new?	39
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML	39
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease	39
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML	39
External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort	38
Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer	38
Follicular lymphoma and macrophages: impact of approved and novel therapies	38
Genomics of PDGFR-rearranged hypereosinophilic syndrome	38
Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy	38
Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs	38
SGK1 inhibition induces fetal hemoglobin expression and delays polymerization in sickle erythroid cells	37
Membrane bending and sphingomyelinase-associated, sulfatide-dependent hypoxic adhesion of sickle mature erythrocytes	37
Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression	37
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis	37
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	37
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	37
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	37
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma	37
TheCADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11	37
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms	37
Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS	36
Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth	36
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH	36
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	36
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	36
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	35
Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report	35
Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study	35
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	35

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry	35
Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial	35
Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies	34
Atrial arrhythmia in adults with sickle cell anemia: a missing link toward understanding and preventing strokes	34
A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia	34
Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations	34
A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale	34
HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma	34
Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model	34
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	34
Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome	34
Regulatory association of long noncoding RNAs and chromatin accessibility facilitates erythroid differentiation	34
GATA2 deficiency phenotype associated with tandem duplication of GATA2 and overexpression of GATA2-AS1	34
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network	34
NUP98 is rearranged in 5.0% of adult East Asian patients with AML	33
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma	33
Management of iron deficiency in women in Scotland	33
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	33
Inhibition of MICA and MICB shedding enhances memory-like NK-cell–mediated cytotoxicity against multiple myeloma	33
Cardiac events after allo-HCT in patients with acute myeloid leukemia	33
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial	32
Impact of iron overload on incidence of diabetes mellitus, cardiac disease, and death in congenital hemolytic anemias	32
Evaluation of hemoglobin S percent threshold to prevent severe pain events: a secondary analysis of the SIT trial	32
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy	32
Histidine-rich glycoprotein attenuates catheter thrombosis	32
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study	32
On a collision course: SARS-CoV-2 variants and CAR T cells	32
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series	32
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence	32
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	31
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia	31
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding	31
CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities	31
A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis	31
Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease	31
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R	31
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia	31
Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation	31
UM171 enhances fitness and engraftment of gene-modified hematopoietic stem cells from patients with sickle cell disease	31
Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome	31
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies	31
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis	30
Gender and early-career faculty disparities in hematology and oncology board review lecture series	30
In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation	30
Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument	30
LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα	30
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	30
An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia	30
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	30
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	30
Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen	30
Treating lymphoma is now a bit EZ-er	30
Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization	30
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study	30
R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation	30
IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis	30
Allogeneic hematopoietic cell transplantation for adult metachromatic leukodystrophy: a case series	29
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level	29
Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE	29
Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia	29
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease	29
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia	29
Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis	29
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study	29
Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma	29
Haptoglobin 1 allele predicts higher serum haptoglobin concentration and lower multiorgan failure risk in sickle cell disease	29
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	29
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen	29
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes	29
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	28
Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia	28
Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels	28
Search for AL amyloidosis risk factors using Mendelian randomization	28
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS	28
Introduction of an ancient founder glycoprotein VI mutation into the Chilean population	28
SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow	28
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma	28
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies	28
The outcome of older adults with classic Hodgkin lymphoma in British Columbia	28
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	28
IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells	28
Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR inRUNX1deficiency	28
Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT	28
Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function	28
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation	28
Vascular surgery patients with elevated neutrophil-to-lymphocyte ratios have downregulated neutrophil complement RNA expression	28
Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study	28
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication	27
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy	27
A new murineRpl5(uL18) mutation provides a unique model of variably penetrant Diamond-Blackfan anemia	27
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification	27
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate	27
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia	27
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma	27
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS	27